We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/7/2020 11:54 | what rubbish !!! | piedro | |
21/7/2020 11:36 | Gents - the future is by definition uncertain. All we can do is trail a stop behind a rising trend and have the discipline to get out when the trail is violated. In other words, ride the trend for as long as it goes on. That's the only way how we all make money. | tongosti | |
21/7/2020 10:59 | just being realistic which you are not | phillis | |
21/7/2020 10:29 | you didnt but you ascribed a weighty market cap target for what is essentially a lab service business hope you are correct nonetheless | phillis | |
21/7/2020 10:20 | When did I say it invents things? | greg the grinch | |
21/7/2020 10:17 | greg It is just a service business It doesnt invent anything | phillis | |
21/7/2020 10:14 | just re-read the trading statement today re: fall in CRO revenues: '...due to the Covid-19 impact on pass-through revenues and the inclusion in H1 2019 of the £1.6 million one-off revenue...' hopefully CRO revenues will start growing again in H2 once Covid-19 impact starts to wear off. | mfhmfh | |
21/7/2020 10:14 | In 3-5 years a £1B company? | greg the grinch | |
21/7/2020 09:59 | Must admit I sold out a while back but back in again after the Ashfield acquisition. Hoping to see the new PrimeVigilance USA become the main revenue growth driver in the future. Looking for some acceleration from this division in the 2nd half. RM | rampmeister | |
21/7/2020 08:59 | That's right pal you've nailed it - understanding volumes is key to that as big players always leave footprints behind when they start building up positions | tongosti | |
21/7/2020 08:54 | yes, one to watch - could be chronic otherwise all good P. | piedro | |
21/7/2020 08:44 | very happy with these results. anyone concerned about the fall in CRO revenues? | mfhmfh | |
21/7/2020 08:15 | The trick with these small caps is to buy in before they are noticed by the big players. Been here a year now and very pleased with the performance of this company. | firtashia | |
21/7/2020 07:26 | Excellent update fellas - the market proceeds fundamentals and that's the reasons why high volume bo's are always great risk reward opps. Good luck all | tongosti | |
21/7/2020 07:05 | Nice. My best performing holding. :-) | grabster | |
21/7/2020 06:55 | Excellent news let's see how the share price reacts. | blueflame | |
21/7/2020 06:30 | Great update | montynj | |
21/7/2020 06:23 | Excellent update | bermudashorts | |
21/7/2020 06:11 | JPM either had a crystal ball or knew about these results. Excellent progress, let's see if mkt likes them | ayl30 | |
20/7/2020 18:08 | JPM building up a position fellas. Expect fireworks now | tongosti | |
20/7/2020 15:44 | Volumes traded today are 17x 50day average. Huge shift in demand for shares trading at all time highs stacks the odds in favour of an even greater advance. Key word: odds (nothing is certain in this game hence one manages risk carefully). | tongosti | |
20/7/2020 13:24 | Patience, it will come along slowly, all the drugs activity spells more demand for testing, ERGO in a sweet spot | ayl30 | |
20/7/2020 12:14 | £10m trades so far. Much more to follow it seems. Very very legitimate 490 breakout Onwards and upwards fellas | tongosti | |
20/7/2020 08:14 | Decent follow up post that 490 bo. Early doors yet so let's see if this bad boy hold. Momentum proceeds price so odds look good. | tongosti |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions